Clinical Trial Update: Controlled Trial of ABELADRUG200 in Closed, Severe Head Injury [Phase 1, Phase 2]

View source ↗

Summary

A controlled Phase 1/2 trial of ABELADRUG200 for severe head injury (traumatic brain injury) is reported with the study status currently unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Traumatic Brain Injury

Drugs mentioned

• ABELADRUG200

Snippet

Sponsor: Abela Pharmaceuticals, Inc. | Conditions: Severe Head Trauma | Phase 1, Phase 2 | Status: UNKNOWN